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Tejal A Patel1,2, Bhuvanesh Dave1, Angel A Rodriguez1,2, Jenny C Chang1,2*, Edith A Perez3
and Gerardo Colon-Otero3See related review by Patel et al., http://breast-cancer-research.com/content/16/4/419
The online version of the original article can be found under doi:10.1186/s13058-014-0419-5.Erratum
After publication of our review [1], we noted errors to the
legend of Figure 1B, C. The ado-trastuzumab-emtansine
concentration should be 1 μg/ml instead of 1 mg/ml. The
trastuzumab concentration should be 10 μg/ml instead of
10 mg/ml. The lapatinib concentration should be 10 μM
instead of 10 mM (Please see Figure 1, a corrected version
of the original Figure 1).
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Figure 1 Dual blockade with antibody–drug conjugate and targeted therapy. (A) SCID Beige mice were injected with 1 million cells per
mouse in the estrogen receptor-positive, human epidermal growth factor receptor (HER)-positive cell line called BT474-m1. These animals were
randomized into six groups and treated with: vehicle control; trastuzumab (5 mg/kg once weekly); lapatinib (100 mg/kg daily); ado-trastuzumab-
emtansine (TDM-1; 5 mg/kg weekly); trastuzumab (5 mg/kg once weekly) + lapatinib (100 mg/kg daily); or TDM-1 (5 mg/kg weekly) + lapatinib
(100 mg/kg daily). Tumor volume fold-change will be measured twice weekly post treatment. (B), (C) BT474 and SKBR3 HER2-positive cell lines
were treated with the following: vehicle control; TDM-1 (1 μg/ml); trastuzumab (10 μg/ml) + lapatinib (10 μM) 4); or TDM-1 (1 μg/ml) + lapatinib
(10 μM). Cells were assessed for proliferation and apoptosis post treatment. *Data analyzed by one way analysis of variance followed by Tukey
analysis for a pairwise comparison of different groups, P < 0.05. T, trastuzumab; L, lapatinib. Data from J Chang, unpublished data.
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